Grenada

Resilience System


You are here

Home

Treatments

Pfizer more than doubles price of Covid-19 medication Paxlovid, shortages in poorer countries

Thu, 2023-10-19 11:12 — mike kraft
Pfizer more than doubles price of lifesaving Covid-19 medication Paxlovid as US transitions out of pandemic phase | CNN The price of the lifesaving Covid-19 antiviral medication Paxlovid will more than double as the United States transitions out of the emergency phase of the pandemic, drugmaker Pfizer said Wednesday. Meg Tirrell CNN

The list price, before insurance, will be $1,390 for a five-day course, Pfizer said in a statement. That’s 2.6 times higher than the $530-per-course price paid by the US government, which provided Paxlovid free to patients during the pandemic. The Wall Street Journal first reported the new price.

Country / Region Tags: 
Africa
Global
Latin America
United States
General Topic Tags: 
COVID-19
Treatments
Disease
Health
Pandemics
Public Health
Scarcity
Problem, Solution, SitRep, or ?: 
Situation Report

Pre-pandemic efficiently managed hospital ICU's had lower COVID-19 deaths --study

Wed, 2023-10-18 10:22 — mike kraft
Prepandemic ICU performance related to lower COVID mortality rates Caiaimage/Martin Barraud/iStock CIDRAP

... in Chest, a review of intensive care units (ICUs) across 10 Brazilian states shows that those with lower mortality rates pre-pandemic saw lower COVID-19 death rates.

Moreover, efficiently managed ICUs also saw lower mortality from the novel coronavirus, suggesting that hospital management is directly linked to patient outcomes.

...

Country / Region Tags: 
Brazil
Global
General Topic Tags: 
COVID-19
Treatments
Disease
Health
Hospitals
Public Health
Problem, Solution, SitRep, or ?: 
Analysis

Price of Covid-19 antiviral Paxlovid expected to rise next year, raising access concerns

Mon, 2023-10-16 18:37 — mike kraft
Price of lifesaving Covid-19 antiviral Paxlovid expected to rise next year, raising concerns about access | CNN The price of the lifesaving Covid-19 medication Paxlovid is likely to rise next year for most patients as the United States continues to transition out of the emergency phase of the pandemic, sparking concerns among doctors that it will become less accessible. Meg Tirrell CNN

 

Country / Region Tags: 
Global
United States
General Topic Tags: 
COVID-19
Treatments
Disease
Public Health
Economics
Problem, Solution, SitRep, or ?: 
Situation Report

Advice on Isolating if You Catch COVID-19

Thu, 2023-10-12 18:16 — mike kraft
Do I Still Need to Isolate If I Get COVID-19? What to know about the CDC's guidance. TIME

...

Country / Region Tags: 
Global
United States
General Topic Tags: 
COVID-19
Symptoms
Boosters
Treatments
Contagion
Health
Public Health
Problem, Solution, SitRep, or ?: 
Analysis

Drug prices: Major drugmakers agree to negotiate drug prices with U.S. government

Tue, 2023-10-03 19:21 — mike kraft
Drugmakers agree to negotiate drug prices with government, White House says The manufacturers of 10 prescription drugs — including Eliquis, Xarelto and Januvia — will take part in the negotiations. NBC News

Major drug companies including Johnson & Johnson, Merck and Bristol Myers Squibb have committed to participate in Medicare drug price negotiations with the federal government, the Biden administration said Tuesday.

...

Country / Region Tags: 
United States
General Topic Tags: 
Treatments
Government
Health
Policy
Public Health
Problem, Solution, SitRep, or ?: 
Situation Report

Paxlovid cuts hospitalization, death only in COVID patients with weak immune systems -- Canadian study

Tue, 2023-10-03 10:44 — mike kraft

 

Study: Paxlovid cuts hospitalization, death only in at-risk COVID patients with weak immune systems seb_ra / iStock CIDRAP

...in JAMA Network Open, an observational Canadian study ties the antiviral drug combo nirmatrelvir-ritonavir (Paxlovid) to a lower risk of hospitalization or death only in very high-risk COVID-19 patients with weakened immune systems.

...

 

 

Country / Region Tags: 
Canada
General Topic Tags: 
COVID-19
Symptoms
Treatments
Data
Demographics
Disease
Health
Public Health
Research
Problem, Solution, SitRep, or ?: 
Analysis
Situation Report

Helping determine if it is a cold, flu or Covid-19 -A CNN medical consultant's suggestions

Fri, 2023-09-29 11:01 — mike kraft
Is it cold, the flu or Covid-19? A doctor helps sort it out | CNN As more people start getting the sniffles, you may wonder if it’s a cold, the flu or Covid-19? Dr. Leana Wen helps us sort out those cold-like symptoms and decide what to do next. Katia Hetter CNN

...

Dr. Wen:

Country / Region Tags: 
Global
United States
General Topic Tags: 
COVID-19
Seasonal Flu
Symptoms
Treatments
Disease
Medical Testing
Public Health
Problem, Solution, SitRep, or ?: 
Analysis
Other

U.S. Government program to develop the next generation of Covid vaccines makes $433 million research grant

Wed, 2023-09-27 18:42 — mike kraft
U.S. government’s next-gen Covid effort gives small biotech up to $433 million The U.S. government said it would give a small biotechnology firm, Gritstone bio, up to $433 million to conduct a 10,000-volunteer clinical trial testing a new approach to creating a Covid vaccine. Matthew Herper STAT
Country / Region Tags: 
United States
General Topic Tags: 
COVID-19
Treatments
Disease Prevention
Government
Public Health
Research
Vaccinations
Problem, Solution, SitRep, or ?: 
Situation Report

Both Paxlovid, molnupiravir lower COVID Omicron deaths, hospitalizations -- studies

Fri, 2023-09-22 10:17 — mike kraft
Both Paxlovid, molnupiravir lower COVID Omicron deaths, hospitalizations, studies conclude AsiaVision / iStock CIDRAP

Two new studies describe the benefits of the antiviral drugs nirmatrelvir-ritonavir (Paxlovid) and molnupiravir in reducing SARS-CoV-2 Omicron hospitalizations and death, with one finding that the former is more effective than the latter at lowering death rates.

Country / Region Tags: 
Global
United States
General Topic Tags: 
COVID-19
Treatments
Data
Disease
Health
Medical Testing
Mutations
Public Health
Research
Problem, Solution, SitRep, or ?: 
Analysis

Depressant fluvoxamine not effective in reducing COVID inflammation--study

Tue, 2023-09-19 19:43 — mike kraft
Study shows no benefits of antidepressant for COVID-19 symptoms - UPI.com Researchers studied fluvoxamine because previous evidence suggested that it might be able to reduce inflammation caused by the virus. UPI

 

A clinical trial designed to test repurposed medications for their impact on fighting COVID-19 has found no benefit to taking the antidepressant fluvoxamine (Luvox) to ease coronavirus symptoms.

Country / Region Tags: 
Global
United States
General Topic Tags: 
COVID-19
Treatments
Disease
Research
Problem, Solution, SitRep, or ?: 
Analysis

Pages

Subscribe to Treatments
howdy folks
Page loaded in 0.549 seconds.